Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 14/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.40 |
| ▸ | HTR2C | P28335 | 6/20 | 0.40 |
| ▸ | HTR2B | P41595 | 6/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17321057 | 0.85 | MEN1 (0.43) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL426895 | 0.84 | HRH1 (0.44) | SLC6A4SLC6A2HTR2CHTR2BSLC6A3 | |
| SCHEMBL23898253 | 0.82 | SLC6A4 (0.41) | SLC6A4SLC6A2HTR2CHTR2BHTR2A | |
| SCHEMBL26394117 | 0.81 | SLC6A4 (0.46) | SLC6A4SLC6A2HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL72150 | 0.81 | SLC6A4 (0.40) | SLC6A4SLC6A2HTR2CHTR2BHTR2A | |
| SCHEMBL428288 | 0.77 | BRAF (0.41) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL12426535 | 0.77 | MEN1 (0.46) | SLC6A4SLC6A2 | |
| SCHEMBL911385 | 0.77 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL911386 | 0.77 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL83664 | 0.75 | SLC6A4 (0.64) | SLC6A4SLC6A2HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7514564-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514564-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1798230-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | SLC6A4 936/4885SLC6A2 646/4885HTR2C 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.